Case report : convalescent plasma, a targeted therapy for patients with CVID and severe COVID-19

Van Damme, Karel; Tavernier, Simon; Van Roy, Nele; De Leeuw, Elisabeth; Declercq, Jozefien; Bosteels, Cedric; Maes, Bastiaan; De Bruyne, Marieke; Bogaert, Delfien; Bosteels, Victor; Hoste, Levi; Naesens, Leslie; Maes, P; Grifoni, A; Weiskopf, D; Sette, A; Depuydt, Pieter; Van Braeckel, Eva; Haerynck, Filomeen; Lambrecht, Bart

Case report : convalescent plasma, a targeted therapy for patients with CVID and severe COVID-19

Karel Van Damme (UGent) , Simon Tavernier (UGent) , Nele Van Roy, Elisabeth De Leeuw (UGent) , Jozefien Declercq (UGent) , Cedric Bosteels (UGent) , Bastiaan Maes (UGent) , Marieke De Bruyne (UGent) , Delfien Bogaert (UGent) , Victor Bosteels (UGent) , et al.

(2020) FRONTIERS IN IMMUNOLOGY. 11.

Author

Karel Van Damme (UGent) , Simon Tavernier (UGent) , Nele Van Roy, Elisabeth De Leeuw (UGent) , Jozefien Declercq (UGent) , Cedric Bosteels (UGent) , Bastiaan Maes (UGent) , Marieke De Bruyne (UGent) , Delfien Bogaert (UGent) , Victor Bosteels (UGent) , Levi Hoste (UGent) , Leslie Naesens (UGent) , P Maes, A Grifoni, D Weiskopf, A Sette, Pieter Depuydt (UGent) , Eva Van Braeckel (UGent) , Filomeen Haerynck (UGent) and Bart Lambrecht (UGent)

Organization

Abstract

The disease course of COVID-19 in patients with immunodeficiencies is unclear, as well as the optimal therapeutic strategy. We report a case of a 37-year old male with common variable immunodeficiency disorder and a severe SARS-CoV-2 infection. After administration of convalescent plasma, the patient's condition improved rapidly. Despite clinical recovery, viral RNA remained detectable up to 60 days after onset of symptoms. We propose that convalescent plasma might be considered as a treatment option in patients with CVID and severe COVID-19. In addition, in patients with immunodeficiencies, a different clinical course is possible, with prolonged viral shedding.

Keywords

convalescent plasma, COVID-19, common variable immunodeficiency disorders, immunodeficiencies, case report

Downloads

Download

fimmu-11-596761.pdf
- full text (Published version)
- |
- open access
- |
- PDF
- |
- 1.76 MB

Citation

Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-8685445

MLA: Van Damme, Karel, et al. “Case Report : Convalescent Plasma, a Targeted Therapy for Patients with CVID and Severe COVID-19.” FRONTIERS IN IMMUNOLOGY, vol. 11, 2020, doi:10.3389/fimmu.2020.596761.
APA: Van Damme, K., Tavernier, S., Van Roy, N., De Leeuw, E., Declercq, J., Bosteels, C., … Lambrecht, B. (2020). Case report : convalescent plasma, a targeted therapy for patients with CVID and severe COVID-19. FRONTIERS IN IMMUNOLOGY, 11. https://doi.org/10.3389/fimmu.2020.596761
Chicago author-date: Van Damme, Karel, Simon Tavernier, Nele Van Roy, Elisabeth De Leeuw, Jozefien Declercq, Cedric Bosteels, Bastiaan Maes, et al. 2020. “Case Report : Convalescent Plasma, a Targeted Therapy for Patients with CVID and Severe COVID-19.” FRONTIERS IN IMMUNOLOGY 11. https://doi.org/10.3389/fimmu.2020.596761.
Chicago author-date (all authors): Van Damme, Karel, Simon Tavernier, Nele Van Roy, Elisabeth De Leeuw, Jozefien Declercq, Cedric Bosteels, Bastiaan Maes, Marieke De Bruyne, Delfien Bogaert, Victor Bosteels, Levi Hoste, Leslie Naesens, P Maes, A Grifoni, D Weiskopf, A Sette, Pieter Depuydt, Eva Van Braeckel, Filomeen Haerynck, and Bart Lambrecht. 2020. “Case Report : Convalescent Plasma, a Targeted Therapy for Patients with CVID and Severe COVID-19.” FRONTIERS IN IMMUNOLOGY 11. doi:10.3389/fimmu.2020.596761.
Vancouver: 1.
Van Damme K, Tavernier S, Van Roy N, De Leeuw E, Declercq J, Bosteels C, et al. Case report : convalescent plasma, a targeted therapy for patients with CVID and severe COVID-19. FRONTIERS IN IMMUNOLOGY. 2020;11.
IEEE: [1]
K. Van Damme et al., “Case report : convalescent plasma, a targeted therapy for patients with CVID and severe COVID-19,” FRONTIERS IN IMMUNOLOGY, vol. 11, 2020.

@article{8685445,
  abstract     = {{The disease course of COVID-19 in patients with immunodeficiencies is unclear, as well as the optimal therapeutic strategy. We report a case of a 37-year old male with common variable immunodeficiency disorder and a severe SARS-CoV-2 infection. After administration of convalescent plasma, the patient's condition improved rapidly. Despite clinical recovery, viral RNA remained detectable up to 60 days after onset of symptoms. We propose that convalescent plasma might be considered as a treatment option in patients with CVID and severe COVID-19. In addition, in patients with immunodeficiencies, a different clinical course is possible, with prolonged viral shedding.}},
  articleno    = {{596761}},
  author       = {{Van Damme, Karel and Tavernier, Simon and Van Roy, Nele and De Leeuw, Elisabeth and Declercq, Jozefien and Bosteels, Cedric and Maes, Bastiaan and De Bruyne, Marieke and Bogaert, Delfien and Bosteels, Victor and Hoste, Levi and Naesens, Leslie and Maes, P and Grifoni, A and Weiskopf, D and Sette, A and Depuydt, Pieter and Van Braeckel, Eva and Haerynck, Filomeen and Lambrecht, Bart}},
  issn         = {{1664-3224}},
  journal      = {{FRONTIERS IN IMMUNOLOGY}},
  keywords     = {{convalescent plasma,COVID-19,common variable immunodeficiency disorders,immunodeficiencies,case report}},
  language     = {{eng}},
  pages        = {{6}},
  title        = {{Case report : convalescent plasma, a targeted therapy for patients with CVID and severe COVID-19}},
  url          = {{http://dx.doi.org/10.3389/fimmu.2020.596761}},
  volume       = {{11}},
  year         = {{2020}},
}

Altmetric: View in Altmetric
Web of Science: Times cited:

Academic Bibliography

Case report : convalescent plasma, a targeted therapy for patients with CVID and severe COVID-19

Downloads

Citation

Contents

Support

Contact